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The objective of this study was to compare the level of total antioxidant status (TAS) in type 2 diabetic and normal Palestinian
subjects as well as the major factors influencing TAS levels. A sample of convenience composed of 212 type 2 diabetic and 208
normal subjects above the age of 40 were recruited. Only 9.8% of the subjects had normal body mass index (BMI) levels (<25), 29%
were overweight (≥25 to <30), and 61.2% were obese (≥30). The mean levels of TAS were significantly higher in diabetic compared
to control subjects (2.18 versus 1.84mM Trolox, P = 0.001) and in hypertensive subjects compared to subjects with normal blood
pressure (BP). Mean TAS levels were higher in obese compared to nonobese subjects (2.12 versus 1.85mMTrolox, P = 0.001). Mean
TAS levels were similarly higher in subjects with high fasting plasma glucose (FPG) compared to normal FPG (2.19 versus 1.90mM
Trolox) and high HbA1c (≥6.5%) compared to HbA1c < 6.5% (2.14 versus 1.91mM Trolox). Multivariate analysis revealed that only
diabetic status (P = 0.032) and the level of education (P = 0.036) were significantly associated with TAS. In conclusion diabetic
patients had 18.5% increase in TAS levels compared to control subjects.
1. Introduction
The prevalence of diabetes in the Middle East countries
is among the highest in the world [1, 2]. The prevalence
of diabetes among the Palestinian population is about 12%
[3, 4], with the highest (about 20%) in the United Arab
Emirates [5, 6]. Four of the top ten countries with the
highest prevalence of prediabetes are in the Middle East
Arab states of the Gulf (Kuwait, Qatar, United Arab Emirates
(UAE), and Bahrin with prevalence of 17.9%, 17.1%, 16.6%,
and 16.3%, resp.) [2]. Risk factors for type 2 diabetes mellitus
among the Palestinian community including obesity, genetic
predisposition, and sedentary life style are clearly evident
[7]. Oxidative stress, defined as excess formation and/or
insufficient removal of highly reactive molecules such as
reactive oxygen species (ROS) and reactive nitrogen species
(RNS), increases in diabetes when free radical production
exceeds the body’s ability to neutralize them [8, 9]. Excess
generation of free radicals has been associated with tissue
damage and complications in diabetic patients [10–19].
Despite the agreement on the increase of free radicals in
diabetic patients, the level of antioxidants in diabetic patients
has been reported to decrease [20–25], increase [26–28], or
stay the same [10]. The effect of diabetes on total antioxidant
levels seems to be complicated by the effect of diabetes on
individual antioxidant systems. Kimura et al. [27] reported
an increase in extracellular superoxide dismutase (SOD)
whereas Palanduz et al. [29] reported a decrease in plasma
glutathione peroxidase levels and an increase in plasma SOD
at the same time. Al-Rawi [30] also reported an increase in
SOD in diabetic patients in the UAE.
In this study we investigated for the first time the
association of TAS in Palestinian type 2 diabetic subjects with
several environmental and biochemical parameters known to
affect or be affected by diabetes.
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2. Materials and Methods
2.1. Participants. Written informed consent was obtained
from all participants involved in the study. A sample of
convenience composed of 209 known type 2 diabetic patients
treated at UNRWA clinics for diabetes (70 males and 139
females) and 208 known normal subjects (68 males and
140 females) above the age of 40 were recruited from three
major central clinics in the West Bank administered by
UNRWA. Seventy-six out of the 208 normal subjects have
impaired fasting plasma glucose (≥5.6 to <7.0mmol/L). All
subjects were instructed to fast for 10–12 hours before coming
to the clinics at 8:00 am. A special questionnaire designed
to collect sociodemographic, lifestyle, family history, and
health related information was filled for all participants
during direct interviews with the researchers. Subjects who
administered antioxidants as supplements like vitamins were
excluded from the study. Diabetic subjects were on different
medications, mainly metformin. Those who were on insulin
were excluded from the study. Blood pressure (BP), weight,
and height weremeasured by themedical teams in the clinics.
Body mass index (BMI) in kg/m2 was categorized as normal
(BMI < 25), overweight (BMI ≥ 25 to <30), and obese (BMI
≥ 30). Diabetic subjects were not on special diets. The study
protocol was approved by Al-Quds University and UNRWA
ethical committees and all participants gave their informed
consent.
2.2. Analytical Procedures. Blood samples were collected
from all subjects and were tested for their total antioxi-
dant status (TAS), fasting plasma glucose (FPG), glycated
hemoglobin (HbA1c), and total lipid profile including total
cholesterol (TC), triacylglycerol (TG), low density lipo-
protein-cholesterol (LDL-C), and high density lipoprotein-
cholesterol (HDL-C). Serum for TAS analysis was separated
using refrigerated centrifuge under dim light and kept frozen
at −80∘C for two weeks before analysis.
The antioxidant activity was measured as the ability of
the serum to prevent ABTS oxidation in comparison to
Trolox and quantified as millimolar Trolox equivalents
using antioxidant assay kits (Cayman Chemical Co., Ann
Arbor, MI, USA). Glycated hemoglobin was measured by
boronate affinity assay using NycoCard HbA1c Kit (Axis-
shield, Oslo, Norway) that reports a standardized HbA1c
value according to IFCC recommendations. Fasting plasma
glucose and total lipid profile (TC, TG, and HDL) were
measured enzymatically using Chemwell chemistry analyzer
(Awareness Tech, USA), and LDL-C was calculated from
the equation of Friedewald (LDL-C = TC − [HDL-C +
(TG/5)]). The FPG results were categorized as normal (FPG
< 100mg/dL), impaired (FPG 100–125mg/dL), and diabetic
(FPG ≥ 126mg/dL).
2.3. Statistical Analysis. Statistical analysis was performed
using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). Pear-
son’s correlation coefficient was used to test for colinearity
between the continuous variables; statistical comparisons
between different groups for these continuous variables were
carried out using Student’s 𝑡-test and ANOVA and Pearson’s
Table 1: Comparison between diabetic and control subjects with
regard to different parameters.
Parameter Mean ± STD Mean ± STD 𝑃
Control Diabetic
Age (years) 50.0 ± 9.40 55.0 ± 8.31 0.001
Systolic BP (mmHg) 125 ± 16.8 135 ± 16.9 0.001
Diastolic BP (mmHg) 77.5 ± 13.8 80.4 ± 12.3 0.021
FPG mmol/L 5.31 ± 0.83 10.3 ± 4.26 0.001
HbA1c (%) 5.75 ± 0.62 8.14 ± 1.74 0.001
BMI 31.1 ± 6.92 33.3 ± 6.18 0.001
TC mmol/L 5.12 ± 1.04 5.30 ± 1.07 0.089
TG mmol/L 1.58 ± 1.34 2.20 ± 1.34 0.001
HDL mmol/L 1.25 ± 0.37 1.09 ± 0.23 0.001
LDL calculated mmol/L 3.19 ± 0.85 3.24 ± 0.98 0.68
LDL direct mmol/L 3.03 ± 1.05 3.26 ± 1.10 0.046
FPG: fasting plasma glucose; TC: total cholesterol; TG: triglycerides; HDL:
high density lipoprotein; LDL: low density lipoprotein, BMI: body mass
index; HbA1c: hemoglobin A1c.
chi-square statistic was used to assess relationships between
categorical variables. Multivariate analysis implementing
general linear model (ANCOVA) was performed to adjust
and control potential confounders and to test for interactions
between the variables that appeared significantly associated
with the independent variable (TAS) in the bivariate analysis.
Statistical significance was accepted at 𝑃 < 0.05. Because
of missing values the number of each group in different
comparisons is different.
3. Results
Table 1 shows that mean FPG and HbA1c in diabetic subjects
were higher than controls (10.3 versus 5.31mmol/L for FPG
and 8.14 versus 5.75% for HbA1c, resp.). Evidently, the mean
systolic and diastolic BP were significantly higher in diabetic
compared to normal subjects (Table 1). In addition, the mean
triacylglycerol levels were higher whereas HDL levels were
significantly lower in diabetics compared to normal subjects.
Table 1 also shows that BMI for both diabetic and control sub-
jects was above 30 which indicates that control and diabetic
subjects were both obese. Diabetic subjects had significantly
higher mean BMI compared to control subjects (33.3 versus
31.1, resp.). Only 9.8% of the subjects had normal BMI
levels whereas 29% were overweight and 61.2% were obese.
In our study, subjects with high systolic BP (≥140mmHg)
constitute 31.6% whereas those with high diastolic BP
(≥90mmHg) constitute 24.8%. Furthermore, subjects with
abnormal lipid profile including highTC (≥5.5mmol/L), high
TG (≥2.0mmol/L), and high LDL (≥3.5mmol/L) represented
35.0%, 31.9%, and 33.6%, respectively, whereas subjects with
low HDL (<1.0mmol/L) represented 26.6% of the entire
subjects in the study. Moreover, subjects with family history
for diabetes or family history for cardiovascular disease
(CVD) were 59% and 46% of all the studied subjects,
respectively. Our data showed that 64% of subjects with
family history for diabetes also developed diabetes compared
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Table 2: Comparison between mean values of total antioxidants status (TAS) with respect to different parameters.
Parameter TAS (mM Trolox)Mean ± STD (𝑁) 𝑃
Gender Male 2.00 ± 0.79 (128) 0.660
Female 2.04 ± 0.80 (253)
Diabetic status Diabetic 2.18 ± 0.86 (206) 0.000
Control 1.84 ± 0.67 (175)
Systolic blood pressure (mmHg) <140mmHg 1.97 ± 0.78 (261) 0.047
≥140mmHg 2.15 ± 0.83 (118)
Diastolic blood pressure (mmHg) <90mmHg 1.96 ± 0.79 (285) 0.006
≥90mmHg 2.22 ± 0.81 (94)
Total cholesterol (mmol/L) <5.5mmol/L 2.01 ± 0.77 (254) 0.745
≥5.5mmol/L 2.04 ± 0.84 (127)
HDL (mmol/L) <1.0mmol/L 2.02 ± 0.78 (107) 0.959
≥1.0mmol/L 2.02 ± 0.80 (274)
LDL calculated (mmol/L) <3.5mmol/L 2.02 ± 0.80 (260) 0.878
≥3.5mmol/L 2.03 ± 0.80 (121)
LDL direct (mmol/L) <3.5mmol/L 2.01 ± 0.80 (252) 0.752
≥3.5mmol/L 2.04 ± 0.79 (129)
TG (mmol/L) <2.0mmol/L 2.02 ± 0.78 (261) 0.835
≥2.0mmol/L 2.02 ± 0.78 (120)
BMI (kg/m2)
<25 (normal) 2.15 ± 0.59 (33)∗
0.000≥25 to <30 (overweight) 1.78 ± 0.70 (113)∗∗
>30 (obese) 2.12 ± 0.84 (235)∗
HbA1c (%) <6.5% 1.91 ± 0.71 (194) 0.005
≥6.5% 2.14 ± 0.87 (180)
FPG (mmol/L) <7.0 mmol/L 1.90 ± 0.74 (220) 0.000
≥7.0 mmol/L 2.19 ± 0.85 (161)
Smoking
Current smoker 1.99 ± 0.82 (58)
0.782Former smoker 1.96 ± 0.87 (35)
Never smoker 2.04 ± 0.79 (281)
FPG (mmol/L)
Normal 1.80 ± 0.75 (106)∗
0.000Impaired FPG 1.92 ± 0.55 (70)∗
Diabetic 2.17 ± 0.87 (205)∗∗
Educational status
Illiterate 2.09 ± 0.76 (69)∗
0.007Less than high school 2.11 ± 0.83 (199)
∗
High school 1.96 ± 0.71 (51)
Diploma and above 1.72 ± 0.73 (62)∗∗
Family history for diabetes Present 2.08 ± 0.84 (227) 0.049
Absent 1.92 ± 0.71 (151)
Family history of CVD Present 2.11 ± 0.86 (168) 0.048
Absent 1.94 ± 0.73 (207)
∗
𝑃 < 0.05 from ∗∗. Control subjects have either normal fasting plasma glucose (FPG < 100mg/dL or impaired FPG 100–125mg/dL); HDL: high density
lipoprotein; LDL: low density lipoprotein; TG: triglycerides; BMI: body mass index; HbA1c: hemoglobin A1c; CVD: cardiovascular disease. Except for diabetic
status, all subjects were classified according to indicated parameters regardless of having diabetes or not.
to 31% for those subjects with no such family history for
diabetes (𝑃 = 0.001). However, the percentage of subjects
who developed diabetes with family history for CVD did not
significantly differ between diabetic and control subjects (51%
versus 48%, 𝑃 = 0.298). As expected, obesity was positively
associated with the diabetes where 58% of obese subjects
had diabetes compared to 38% of nonobese individuals
(𝑃 = 0.001).
Table 2 shows that themean levels of TAS are significantly
higher in diabetic subjects compared to control subjects
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(2.18 versus 1.84mM Trolox resp., 𝑃 = 0.001). Mean TAS
levels were also significantly higher in hypertensive subjects
(systolic BP ≥ 140mmHg or diastolic BP ≥ 90) compared to
subjects with normal BP (systolic < 140mmHg or diastolic
BP < 90mmHg). In addition obese subjects had higher
mean TAS levels compared to nonobese subjects (normal
and overweight) [2.12 ± 0.84 versus 1.85 ± 0.70mM Trolox
resp., 𝑃 = 0.001]. Mean TAS levels were also similarly higher
in subjects with high FPG (FPG ≥ 7.0mmol/L) and HbA1c
(HbA1c ≥ 6.5). Evidently, subjects with family history for
diabetes or family history for CVD had significantly higher
mean levels of TAS compared to subjects without family
history for diabetes or CVD. In our study, the abnormal
lipid profile among diabetic subjects does not seem to affect
TAS levels since subjects with abnormal lipid profile had
no significant difference in TAS levels compared to subjects
with normal lipid profile (Table 2). Our diabetic subjects had
higher mean age compared to normal subjects (55 versus 50,
𝑃 = 0.001). However, when a subset group of 148 subjects
with similar age were taken (51.5 ± 5.43 years for diabetic
subjects and 51.8 ± 9.13 years for control subjects), the mean
levels of TAS in diabetic subjects maintained a significantly
higher value compared to control subjects (2.19 ± 0.85 versus
1.86 ± 0.65, 𝑃 = 0.001, resp.). In addition, diabetic subjects
had significantly highermean TAS levels than controls within
the obese and overweight groups (2.24 versus 1.95mMTrolox
within the obese and 1.99 versus 1.59mM Trolox within
the overweight subjects, resp.). The educational level seems
to significantly affect TAS levels since subjects with higher
educational levels (diploma and above) had lower mean TAS
levels compared to subjects with lower educational level (less
than high school and including illiterates) (1.72 versus 2.09,
𝑃 = 0.007, resp.) This is consistent with the association
of educational level with developing diabetes, where only
28% of subjects with higher education level (diploma and
above) had diabetes compared to 64% for the illiterate
(𝑃 = 0.001).
Using Pearson’s correlation coefficients, Table 3 shows
significant relationships betweenTAS levels and the indicated
parameters related to diabetes including FPG (𝑟 = 0.129,
𝑃 = 0.012), HbA1c (𝑟 = 0.156, 𝑃 = 0.002,), BMI (𝑟 = 0.117,
𝑃 = 0.022), and systolic BP (𝑟 = 0.1, 𝑃 = 0.019). How-
ever, whenmultivariate analysis was performed between TAS
as an independent variable and all parameters that were
significantly associated with it in the univariate analysis
(Table 4), the results revealed that the only parameters that
remained to have significant association with TAS were
diabetic status (𝑃 = 0.032) and level of education (𝑃 = 0.036).
4. Conclusions
The implications of increased free radicals and oxidative
stress in the development, pathogenesis, and complications of
diabetes mellitus [11, 12, 31, 32] and CVD [33] are very strong
and well documented despite the inconsistency of the clinical
trials using antioxidants in the treatment regimens of diabetes
[33–38]. In this study several variables were detected to have
an association with the TAS level at the univariate level.
Diabetic subjects had 18.5% increase in TAS levels compared
to controls.
The effect of diabetes duration on antioxidant levels
represents another subject of controversy. In our study, at the
univariate level of analysis there was a slight negative corre-
lation between TAS levels and years of diabetes (𝑟 = −140);
however this decrease is not statistically significant. Whiting
et al. [39] reported a decrease in the levels of antioxidants
in diabetic subjects after 4–6 years of illness while no effect
was observed in two years or less. Whether complications of
the disease are correlated with the levels of antioxidants is
not clear. Opara et al. [22] reported a decrease in antioxidant
levels in diabetic subjects with complications while Srivatsan
et al. [28] found an increase in antioxidant levels in diabetic
subjects without complications. Most diabetic subjects in
our study seem to have no obvious complications which is
consistent with the notion that the increase in free radicals
seems to be associated first with an increase in antioxidant
levels and with the progression of the disease the antioxidant
levels decrease and complications eventually develop.
The observed significant correlation between TAS with
several continuous variables, like systolic BP, FPG, HbA1c,
and BMI (𝑟 = 0.120, 0.129, 0.156, and 0.117, resp.), and
noncontinuous variables including education, family history
of diabetes, and CVD is relatively not very strong and
seems to be mediated through diabetes. This is evident
by the multivariate analysis which revealed only diabetes
and education to be statistically significant while the effect
of education on TAS may also be through diabetes. The
multivariate model with these two variables detected as
the significant determinants of TAS could have explained
about 10% of the variability in TAS levels. This suggests that
other determinants might be involved including genetic and
environmental factors. It is not clear in our study whether
the effect of diabetes on TAS is influenced by the nutritional
habits of participating subjects, since fresh vegetables and
fruits are major components of the Palestinian food and food
is known to affect antioxidant levels [20, 40–43].The effect of
nutritional status on TAS in the Palestinian society needs to
be independently evaluated in future studies. One apparent
complication in the interpretation of the obtained results in
this study is the fact that more than 90% of the participating
subjects are either overweight or obese. However, when TAS
levels were normalized for BMI, the effect of diabetes on TAS
still showed diabetic subjects to have higher levels of TAS
which suggest that obesity does not seem to be a primary
determinant of the antioxidant status of individuals. It is
unlikely that the effect of diabetes on TAS levels is due to
medications even though this could not be excluded from
this study. Changes of dietary habits of diabetic subjects
if present could also affect their TAS levels. It is obvious
however that regardless of the effect of diabetes on the levels
of antioxidant status, the increase in antioxidant levels in
diabetic subjects seems to initially reflect adaptation to high
free radicals and the decrease in antioxidant levels apparently
reflects high and overwhelming levels of free radicals which
eventually may play an important role in the development of
diabetes complications. Therefore, under all circumstances,
the health benefits of reducing the levels of free radicals by
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Systolic BP (mm Hg)
r 0.267∗∗ 1
p 0.000
Diastolic BP (mm Hg)
r 0.111∗ 0.582∗∗ 1
p 0.024 0.000
FPG mmol/L
r 0.143∗∗ 0.127∗∗ 0.106∗ 1
p 0.004 0.009 0.031
HbA1c (%)
r 0.204∗∗ 0.234∗∗ 0.151∗∗ 0.776∗∗ 1
p 0.000 0.000 0.002 0.000
TC mmol/L
r 0.102∗ 0.171∗∗ 0.108∗ 0.127∗∗ 0.132∗∗ 1
p 0.038 0.000 0.027 0.009 0.008
TG mmol/L
r 0.057 0.150∗∗ 0.114∗ 0.178∗∗ 0.220∗∗ 0.348∗∗ 1
p 0.244 0.002 0.020 0.000 0.000 0.000
HDL mmol/L
r 0.015 0.051 0.033 −0.156∗∗ −0.172∗∗ 0.260∗∗ −0.238∗∗ 1
p 0.763 0.301 0.503 0.001 0.000 0.000 0.000
LDL mmol/L
r 0.069 0.036 0.032 0.099∗ 0.067 0.845∗∗ −0.013 0.194∗∗ 1
p 0.170 0.472 0.518 0.048 0.187 0.000 0.798 0.000
BMI
r −0.030 0.092 0.146∗∗ 0.101∗ 0.090 −0.029 0.033 −0.012 −0.046 1
p 0.539 0.060 0.003 0.040 0.070 0.560 0.505 0.809 0.362
DM years
r 0.285∗∗ 0.133 0.059 0.312∗∗ 0.408∗∗ −0.067 0.070 −0.016 −0.119 −0.245∗∗ 1
p 0.000 0.064 0.414 0.000 0.000 0.351 0.332 0.820 0.108 0.001
TAS
r 0.085 0.120∗ 0.050 0.129∗ 0.156∗∗ −0.008 −0.054 0.055 0.033 0.117∗ −0.140 1
p 0.100 0.019 0.334 0.012 0.002 0.876 0.296 0.286 0.527 0.022 0.055
r = Pearson coefficient; ∗∗𝑃 < 0.01 level (two-tailed); ∗𝑃 < 0.05 level (two-tailed). FPG: fasting plasma glucose; HDL: high density lipoprotein; LDL: low
density lipoprotein; TC: total cholesterol; TG: triglycerides; BMI: body mass index; HbA1c: hemoglobin A1c; DM: diabetes mellitus.
changing dietary habits and supplementation of antioxidant
like vitamins in diabetic and nondiabetic subjects should
receive more careful evaluation.
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Table 4: Results of multivariate analysis for predictors of the TAS level.
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Family history for CVD Present 2.032 ± 0.070 (165) 1.848 3.145 0.077
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Systolic BP 0.892 1.518 0.219
BMI 0.906 1.542 0.215
a
𝑅 Squared = 0.096 (adjusted 𝑅 squared = 0.063).
Analysis was performed using univariate general linear model (ANCOVA) as the potential predictors included categorical and continuous variables. TAS level
was assessed as the dependent variable. Only variables that were significantly associated with TAS in the univariate analysis were included in the model. CVD:
cardiovascular disease; BMI: body mass index; BP: blood pressure.
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